Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease	Recruiting	Phase 3	2022-04-25		NCT05342792

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Cancer Hospital of Guizhou Medical University	3
Cancer Hospital of Guangxi Medical University	22
Chongqing University Cancer Hospital	41
Fifth Affiliated Hospital, Sun Yat-Sen University	41
First People's Hospital of Foshan	44
Hubei Cancer Hospital	29
Hunan Cancer Hospital	66
Shandong Provincial Hospital	112
Sun Yat-sen University	606
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	164
Tongji Hospital	276
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319
Xiangya Hospital of Central South University	162

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sun Yat-sen University Cancer Center	Guangzhou	China	315